Get started

200ma

$HUSAHouston American Energy Corp., an independent energy company, acquires, explores for, develops, and produces natural gas, crude oil, and condensate. Its oil and gas properties are located primarily in the Texas Permian Basin, the onshore Texas and Louisiana Gulf Coast region, and in the South American country of Colombia. As of December 31, 2020, the company owned interests in four gross wells. Houston American Energy Corp. was incorporated in 2001 and is based in Houston, Texas.
AMEX:HUSALong
by BADQOMOCAWGOWLD
SHort Opportunity on AUDCADFX:AUDCAD As we can see in the analysis Above, The pair has been on a downtrend since April 2021 based on the 200 Moving Average Currently, it has just touched the 200 MA line again and I expect a sell from on a Daily Timeframe. There is also a trendline that has been valid since July 2021, and it just touch the trendline resistance. There is also a Double top pattern on 4hrs Timeframe NB The pair just completed the XABCD pattern on a weekly timeframe, meaning the pair just started a bullish run on a weekly TF so trade with care That is my submission
Short
by Adhemola
6
$VLDRVelodyne Lidar, Inc. provides real-time three-dimensional vision for autonomous systems worldwide. Its sensor and software solutions provide flexibility, quality, and performance to meet the needs of a range of industries, including autonomous vehicles, advanced driver assistance systems, robotics, unmanned aerial vehicles, and smart cities and security. The company also provides Vella software, a data curation software platform designed to deliver a set of safety and autonomy applications to any vehicle that utilizes a Velarray lidar. Velodyne Lidar, Inc. was founded in 1983 and is headquartered in San Jose, California.
VLong
by BADQOMOCAWGOWLD
2
SPY perspective for the weekMy perspective on this weeks market action. First idea, hope it's helpful! Historically the Daily 200ma is a strong bullish or bearish pivot, and has formed a perfect resistance line. In addition a large number of equities are now approaching or testing their own 200ma, and will either find support or break lower, so i am expecting volatility this week as traders will either be stocking up or panic selling. I'm looking to take a swing position to capitalize on a move above or below our recently formed congestion pattern. ]If SPY closes a 1hr candle above 200ma and resistance i will be looking for long setups for the next week or two. If SPY breaks below recent support and fails to close above 200ma, i will go short as i expect to break down further for a full 15-20% correction from ATHs. We can of course continue sideways in this channel, which i think would signal accumulation, and will sit on my hands for a while longer, but with current market conditions i think this is the least likely scenario. Happy fishing!
AMEX:SPY
by Bassanaut
$ARDS Target PTs 4.30-6 and higherH.C. Wainwright Bullish on Aridis Pharmaceuticals Covid-19 Antibody Cocktail Aridis Pharmaceuticals CEO Discusses Monoclonal Antibody Cocktail Protection Against COVID-19 Omicron Variant and Other Viruses in Fox Business Interview LOS GATOS, Calif., Dec. 21, 2021 /PRNewswire/ -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to treat life-threatening infections, announced today that Vu Truong, Ph.D., Chief Executive Officer, was interviewed on Varney & Co., hosted by Stuart Varney, on Fox Business. Key Highlights: AR-703, one of the components of the AR-701 cocktail, binds to the 'S2' stalk region of coronavirus spike proteins that is responsible for viral fusion and entry into host cells, and binds to the Omicron variant with no loss in affinity as compared to the original Wuhan strain. In vitro neutralization studies using live coronaviruses showed that AR-701 achieved broad, potent neutralization against all SARS-CoV-2 variants tested, as well as SARS, MERS, and the seasonal 'common cold' betacoronaviruses. In vivo data with multiple animal challenge models that are widely used to evaluate COVID-19 treatments support AR-701's broad efficacy. AR-701 is engineered to be long-acting and is expected to provide relevant drug levels for up to 1 year from prophylactic or therapeutic treatment. Watch the full interview: video.foxbusiness.com About AR-701 AR-701 is a cocktail of two fully human immunoglobulin G1 (IgG1) mAbs discovered from screening the antibody secreting B-cells of convalescent SARS-CoV-2 infected (COVID-19) patients. AR-701 consists of AR-703 and AR-720 mAbs, each neutralizes coronaviruses using distinct mechanisms of action, namely inhibition of viral fusion and entry into human cells (AR-703) and blockage of viral binding to the human 'ACE2' receptor (AR-720). The two mAbs complement and enhance each other in a synergistic fashion, creating a potent first-in-class cocktail. AR-703 binds to the 'S2' stalk region of spike proteins from betacoronaviruses, including the SARS-CoV2 variants (beta, gamma, delta, epsilon), and binds to the Omicron variant with no loss in affinity compared to the original Wuhan strain. Multiple animal challenge models widely used to evaluate COVID-19 treatments support AR-701's broad efficacy, including: AR-701 mAbs administered parenterally, either individually or in combination with one another, eradicated SARS-CoV-2 (Wuhan strain) from the lungs of infected mice. Hamsters infected with the SARS-CoV-2 (Delta variant) and later treated once with inhaled AR-701 mAbs, either individually or in combination, were protected from disease and weight loss. Mice infected with the Severe Acute Respiratory Syndrome virus (SARS) were also protected from disease and weight loss with a single inhaled dose of AR-701. The AR-701 mAbs are engineered to be active for 6-12 months in the blood. AR-701 is being developed as a long-acting intramuscular as well as a self-administered inhaled formulation for the treatment of COVID-19 patients who are not yet hospitalized. AR-701 mAbs were discovered through a collaboration with researchers at the University of Alabama in Birmingham and Texas Biomedical Research Institute (San Antonio, TX). About Aridis Pharmaceuticals, Inc. Aridis Pharmaceuticals, Inc. discovers and develops novel anti-infective therapies to treat life-threatening infections, including anti-infectives to be used as add-on treatments to standard-of-care antibiotics. The Company is utilizing its proprietary ʎPEXTM and MabIgX® technology platforms to rapidly identify rare, potent antibody-producing B-cells from patients who have successfully overcome an infection, and to rapidly manufacture monoclonal antibody (mAbs) for therapeutic treatment of critical infections. These mAbs are already of human origin and functionally optimized for high potency by the donor's immune system; hence, they technically do not require genetic engineering or further optimization to achieve full functionality. The Company is advancing multiple clinical stage mAbs targeting bacteria that cause life-threatening infections such as ventilator associated pneumonia (VAP) and hospital acquired pneumonia (HAP), in addition to preclinical stage antiviral mAbs. The use of mAbs as anti-infective treatments represents an innovative therapeutic approach that harnesses the human immune system to fight infections and is designed to overcome the deficiencies associated with the current standard of care which is broad spectrum antibiotics. Such deficiencies include, but are not limited to, increasing drug resistance, short duration of efficacy, disruption of the normal flora of the human microbiome and lack of differentiation among current treatments. The mAb portfolio is complemented by a non-antibiotic novel mechanism small molecule anti-infective candidate being developed to treat lung infections in cystic fibrosis patients. The Company's pipeline is highlighted below: Aridis' Pipeline AR-301 (VAP). AR-301 is a fully human IgG1 mAb targeting gram-positive Staphylococcus aureus (S. aureus) alpha-toxin and is being evaluated in a global Phase 3 clinical study as an adjunctive treatment of S. aureus ventilator associated pneumonia (VAP). AR-320 (VAP). AR-320 is a fully human IgG1 mAb targeting S. aureus alpha-toxin that is being developed as a preventative treatment of S. aureus colonized mechanically ventilated patients who do not yet have VAP. Phase 3 is expected to be initiated in 2Q22. AR-501 (cystic fibrosis). AR-501 is an inhaled formulation of gallium citrate with broad-spectrum anti-infective activity being developed to treat chronic lung infections in cystic fibrosis patients. This program is currently in Phase 2a clinical development in CF patients. AR-701 (COVID-19). AR-701 is a cocktail of fully human mAbs discovered from convalescent COVID-19 patients that are directed at multiple protein epitopes on the SARS-CoV-2 virus. It is formulated for delivery via intramuscular injection or inhalation using a nebulizer. AR-701 replaces AR-712 as the company's leading COVID mAb candidate. AR-401 (blood stream infections). AR-401 is a fully human mAb preclinical program aimed at treating infections caused by gram-negative Acinetobacter baumannii. AR-101 (HAP). AR-101 is a fully human immunoglobulin M, or IgM, mAb in Phase 2 clinical development targeting Pseudomonas aeruginosa (P. aeruginosa) liposaccharides serotype O11, which accounts for approximately 22% of all P. aeruginosa hospital acquired pneumonia cases worldwide. AR-201 (RSV infection). AR-201 is a fully human IgG1 mAb out-licensed preclinical program aimed at neutralizing diverse clinical isolates of respiratory syncytial virus (RSV).
ALong
by BADQOMOCAWGOWLD
1
$APM Target PTs 7-14 Long term PT 30 and higherAptorum Shares Rise After FDA Orphan Drug Tag For Repurposed Compound For Pediatric Cancer The FDA has granted Orphan Drug Designation to Aptorum Group Limited (NASDAQ: APM) SACT-1, a repurposed small molecule compound for Neuroblastoma. Aptorum Group plans to file an Investigational New Drug Application (IND) to commence a Phase 1b/2a trial for SACT-1 in 2022. Neuroblastoma is one of the most prevailing solid tumor cancers in children, representing 8% - 10% of all childhood tumors, accounting for around 15% of all cancer-related deaths in the pediatric population. Aptorum received its first US patent regarding SACT-1 repurposed drug for various cancers earlier this week. The SACT-1 invention provides a composition and method for treating or preventing the growth of cancerous tumors and/or delaying the onset of cancer from tumor-initiating cells. Price Action: APM shares are up 30.3% at $1.59 during the premarket session on the last check Thursday. See more from Benzinga FDA clears Nuvation Bio's IND Application For NUV-868 In Advanced Solid Tumors EXCLUSIVE: Alfi Inks AI Tech Deal For Improved Passenger Experience At BWI Thurgood Marshall Airport
NASDAQ:APMLong
by BADQOMOCAWGOWLD
1
$PROG Next Target PT 2.25 and higherProgenity, Inc., a biotechnology company, provides develops and commercializes molecular testing products in the United States. It offers Innatal, a noninvasive prenatal screening test offered to women early in pregnancy to screen for chromosome abnormalities, such as down syndrome, trisomy 18, trisomy 13, and sex chromosome disorders through the analysis of cell-free DNA; Preparent that screens for carrier status of hereditary diseases prior to or early in pregnancy; and Riscover, a hereditary cancer screen that analyzes 31 genes associated with inherited risk of 12 types of cancers, including the BRCA1/2 genes for hereditary breast, ovarian, colorectal, endometrial, pancreatic, and other cancer syndromes, as well as for the five genes associated with Lynch syndrome. The company also provides Resura, a noninvasive prenatal test for families at risk for rare single gene disorders; and Preecludia, a preeclampsia rule-out test. In addition, it offers anatomic and molecular pathology tests, and COVID-19 PCR testing services, as well as test products that includes chromosomal microarray for pregnancy loss, which evaluates the genetic cause of miscarriage; maternal serum screening for chromosomal disorders; and preimplantation genetic testing for use with artificial reproductive technologies. Further, the company develops therapeutic solutions for gastrointestinal-related disorders, such as PGN-001, PGN-300, PGN-600, and PGN-OB2. It also owns and operates laboratory. Progenity, Inc. was formerly known as Ascendant MDX, Inc. and changed its name to Progenity, Inc. in November 2013. The company was founded in 2010 and is headquartered in San Diego, California.
PLong
by BADQOMOCAWGOWLD
$SBEV entry PTs 3.25-3.40 Next Target PT 5Splash Beverage Group, Inc. produces, distributes, and markets various beverages in the United States. The company offers hydration and recovery isotonic sport drink under the TapouT Performance brand; and flavored tequilas under the SALT Naturally Flavored Tequila brand. It also sells beverages and groceries online through qplash.com; produces premium wine under the Copa di Vino brand; and offers premium Pulpoloco Sangria. The company is based in Fort Lauderdale, Florida.
AMEX:SBEVLong
by BADQOMOCAWGOWLD
$BBIG Support and ResistanceVinco Ventures, Inc. operates as a consumer product research and development, manufacturing, sales, and fulfillment company in North America, the Asia Pacific, and Europe. It offers toys, plush, homewares, and electronics to retailers, distributors, and manufacturers through e-commerce channels; and personal protective equipment to governmental agencies, hospitals, and distributors. The company was formerly known as Edison Nation, Inc. and changed its name to Vinco Ventures, Inc. in November 2020. Vinco Ventures, Inc. was incorporated in 2017 and is based in Fairport, New York.
BLong
by BADQOMOCAWGOWLD
Dow futures idea for short and medium termOn a daily chart, DOW has closed below 200 MA which calls for a bearish sign. However, there is still some support for the rising wedge. The trendline has broken very strongly on weekly. I think we are close to a halfway mark on correction; possibly 4-5% is still left to go. After that, we should see some possible reversal due to the confluence of: - reaching 23.6% on Fibonacci level; - support at the megaphone pattern; - the target of the wedge would be met; and - most of the big tech stock would also be at support.
CBOT_MINI:YM1!
by tradewithmitra
ROKU: IS THIS WHERE WE GO UP AGAIN?ROKU: Weekly chart currently sitting on the 200ma . At historical support -resistance zone. Demark Sequential Buy 9 daily. RSI a bit oversold on weekly. Bullish divergence on daily. Are we bouncing here or do we keep going down? Whatever is it, I like the good risk vs reward long entry here. You might argue that we're going against the trend and you're right, however he odds favour the bulls. Long term investment, swing or short term trade? Your choice. Stop around 155. Trade safe!
NASDAQ:ROKULong
by Elpidaldo
6
NQ Power Range Report with FIB Ext - 1/21/2022 SessionCME_MINI:NQH2022 - PR High: 14754.25 - PR Low: 14684.25 Evening Stats (As of 1:23 AM) - Gap: = N/A - Session Open ATR: 358.08 - Volume: 99k - Open Int: 240k - Trend Grade: Neutral - From ATH: -12.0% (Rounded) Key Levels (Rounded - Think of these as ranges) - Long: 15550 - Mid: 15247 - Short: 14360 Keep in mind this is not speculation or a prediction. Only a report of the Power Range with Fib extensions for target hunting. Do your DD! You determine your risk tolerance. You are fully capable of making your own decisions.
CME_MINI:NQH2022
by mv3trader5
ES1! + VIX possible reversalWhat's bearish: - Rising Wedge pattern - Rejection of the 200MA - A decrease in volume in the last 2-3 trading days - Bearish divergence (red line) - Falling wedge pattern on the VIX (image in the comment) This is a pure technical standpoint, it has nothing to do with fundamentals or the market sentiments Me: Hello I started with stocks 1 year ago. After analyzing many charts, I have accumulate more experience than a newb. Now I'm a newb+. Pls feel free to give me feedback
CME_MINI:ES1!
by gmurugneux